195 related articles for article (PubMed ID: 12962052)
1. [Drug delivery to the brain with nanoparticles].
Aliautdin RN; Kreuter J; Kharkevich DA
Eksp Klin Farmakol; 2003; 66(2):65-8. PubMed ID: 12962052
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Eur J Pharm Biopharm; 2008 Sep; 70(1):75-84. PubMed ID: 18472255
[TBL] [Abstract][Full Text] [Related]
3. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
[TBL] [Abstract][Full Text] [Related]
4. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
[TBL] [Abstract][Full Text] [Related]
5. The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation.
Weiss CK; Kohnle MV; Landfester K; Hauk T; Fischer D; Schmitz-Wienke J; Mailänder V
ChemMedChem; 2008 Sep; 3(9):1395-403. PubMed ID: 18613205
[TBL] [Abstract][Full Text] [Related]
6. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
[TBL] [Abstract][Full Text] [Related]
7. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity.
Rempe R; Cramer S; Hüwel S; Galla HJ
Biochem Biophys Res Commun; 2011 Mar; 406(1):64-9. PubMed ID: 21295549
[TBL] [Abstract][Full Text] [Related]
8. [The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles].
Aliautdin RN; Petrov VE; Langer K; Berthold A; Kreuter J; Kharkevich DA
Eksp Klin Farmakol; 1998; 61(1):17-20. PubMed ID: 9575405
[TBL] [Abstract][Full Text] [Related]
9. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
Gao K; Jiang X
Int J Pharm; 2006 Mar; 310(1-2):213-9. PubMed ID: 16426779
[TBL] [Abstract][Full Text] [Related]
10. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study.
Alyautdin RN; Tezikov EB; Ramge P; Kharkevich DA; Begley DJ; Kreuter J
J Microencapsul; 1998; 15(1):67-74. PubMed ID: 9463808
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier.
Wohlfart S; Khalansky AS; Gelperina S; Begley D; Kreuter J
J Control Release; 2011 Aug; 154(1):103-7. PubMed ID: 21616104
[TBL] [Abstract][Full Text] [Related]
12. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns.
Göppert TM; Müller RH
J Drug Target; 2005 Apr; 13(3):179-87. PubMed ID: 16036306
[TBL] [Abstract][Full Text] [Related]
13. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
Alyautdin RN; Petrov VE; Langer K; Berthold A; Kharkevich DA; Kreuter J
Pharm Res; 1997 Mar; 14(3):325-8. PubMed ID: 9098875
[TBL] [Abstract][Full Text] [Related]
14. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles.
Kuo YC; Su FL
Int J Pharm; 2007 Aug; 340(1-2):143-52. PubMed ID: 17418986
[TBL] [Abstract][Full Text] [Related]
15. Polymeric nanoparticles for the drug delivery to the central nervous system.
Tosi G; Costantino L; Ruozi B; Forni F; Vandelli MA
Expert Opin Drug Deliv; 2008 Feb; 5(2):155-74. PubMed ID: 18248316
[TBL] [Abstract][Full Text] [Related]
16. Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats.
Bagad M; Khan ZA
Int J Nanomedicine; 2015; 10():3921-35. PubMed ID: 26089668
[TBL] [Abstract][Full Text] [Related]
17. Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain.
Lin Y; Pan Y; Shi Y; Huang X; Jia N; Jiang JY
Nanotechnology; 2012 Apr; 23(16):165101. PubMed ID: 22460562
[TBL] [Abstract][Full Text] [Related]
18. The role of peptides in blood-brain barrier nanotechnology.
Teixidó M; Giralt E
J Pept Sci; 2008 Feb; 14(2):163-73. PubMed ID: 18085720
[TBL] [Abstract][Full Text] [Related]
19. Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood-brain barrier, in human whole blood and in vivo.
Kolter M; Ott M; Hauer C; Reimold I; Fricker G
J Control Release; 2015 Jan; 197():165-79. PubMed ID: 25445700
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter J; Shamenkov D; Petrov V; Ramge P; Cychutek K; Koch-Brandt C; Alyautdin R
J Drug Target; 2002 Jun; 10(4):317-25. PubMed ID: 12164380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
